FA Patients May Benefit From MS Therapy Dimethyl Fumarate, Study Says – Friedreich’s Ataxia News

Dimethyl fumarate, an approved therapy for multiple sclerosis (MS), may help people with Friedreich’s ataxia by increasing the amount of frataxin protein that is deficient in these patients, an international research team has found.

This suggests that the treatment may help overcome the metabolic impairment characteristic of Friedreich’s ataxia and improve the outcomes of those affected by this rare disease.

Read more at: https://friedreichsataxianews.com/2019/06/13/dimethyl-fumarate-may-be-a-potential-therapy-for-friedreichs-ataxia-study-suggests/

Font Resize